Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases
AssigneeRigel Pharmaceuticals, Inc.
InventorsSomasekhar Bhamidipati, Jeffrey Clough, Ankush Argade, Rajinder Singh, Vadim Markovtosov, Pingyu Ding, Jiaxin Yu, Andy Atuegbu, Hui Hong, Ihab Darwish, Sambaiah Thota
Life of this patent
Estimating the term…
Abstract
This invention is directed to methods of treating diseases or conditions associated with JAK2 activity in a mammal comprising the administration of a compound of formula (I): where n, m, Y, R1, R2, R3, R4 and R5 are disclosed herein, or a pharmaceutically acceptable salt.
Claims2
A method of treating a disease or condition associated with JAK2 activity in a mammal, wherein the method comprises administering to the mammal a therapeutically effective amount of 4-(6-(morpholin-4-yl)pyridin-3-yl)-N-(3-methyl-4-((1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)phenyl)pyrimidin-2-amine, or a pharmaceutically acceptable salt thereof, and the disease or condition is leukemia, lymphoma, multiple myeloma, transplant rejection, bone marrow transplant conditions, autoimmune diseases, inflammation, myeloproliferative disorders, polycythemia vera disorder, essential thrombocythemia disorder or primary myelofibrosis.
A method of treating a disease or condition associated with JAK2 activity in a mammal, wherein the method comprises administering to the mammal a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of 4-(6-(morpholin-4-yl)pyridin-3-yl)-N-(3-methyl-4-((1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)phenyl)pyrimidin-2-amine, or a pharmaceutically acceptable salt thereof, and the disease or condition is leukemia, lymphoma, multiple myeloma, transplant rejection, bone marrow transplant conditions, autoimmune diseases, inflammation, myeloproliferative disorders, polycythemia vera disorder, essential thrombocythemia disorder or primary myelofibrosis.
Dependencies are inferred from the claim text.